Collectively, these results highlight the metabolism-inflammation axis as a potential therapeutic target, suggesting that combined modulation of pyroptosis via inflammasome inhibitors and serine metabolism via PHGDH agonists may represent a novel strategy to mitigate neuroinflammation after cerebral ischemia-reperfusion. Here, PHGDH is linked to Cerebral ischemia.